NIH R01 · 2025
Immunoepigenetic targeting of MHC regulators in FAP
Major histocompatibility complex class I and class II (MHC-I/II) members are critical for antigen presentation and adaptive immune responses but are downregulated in sporadic and genetic cases of duodenal and colorectal cancer (CRC), such as Familial Adenomatous Polyposis (FAP). There is an urgent need for novel approaches to reverse MHC-I/II silencing and overcome tumor immune evasion, starting at the adenoma stage. Based on the prior Critique, standard-of-care sulindac and erlotinib (SUL, ERL), and a new histone methyl `reader' inhibitor MAK683 that shows clinical promise, will be repurposed for immune-based interception of FAP. From the rigor of prior research and extensive preliminary…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.